According to Tufts Center for the Study of Drug Development, the average time to build and release a clinical study database is more than 73 days and the average time to lock data at the end of a trial is nearly 39 days.
In 2017, Vertex Pharmaceuticals addressed this issue head-on by setting aggressive internal targets. The company has since reduced database build and release times from 12-14 weeks to six to eight, and data lock times from 22 days to just 15.
On 27/02/2020 mesoblast announced in their half year results.
"The Phase 3 trial of REVASCOR® for advanced chronic heart failure surpassed the number of primary
endpoint events required for trial completion. "
Using the 12-14 weeks time frame we are about due to receive data.
Hold on for the ride.
Glta
Fishywoo
REVASCOR® for advanced chronic heart failure
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.035(3.29%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.09 | $1.03 | $6.850M | 6.578M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 133832 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 25613 | 11 |
View Market Depth
| Last trade - 15.23pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
-0.035 ( 4.12 %) |
||||
| Open | High | Low | Volume | ||
| $1.07 | $1.08 | $1.03 | 1760517 | ||
| Last updated 15.43pm 06/06/2024 ? | |||||
| MSB (ASX) Chart |